MedPath

University Medical Center Groningen

University Medical Center Groningen logo
🇳🇱Netherlands
Ownership
Private
Established
1614-01-01
Employees
10K
Market Cap
-
Website
https://www.umcg.nl

Clinical Trials

920

Active:161
Completed:310

Trial Phases

6 Phases

Early Phase 1:5
Phase 1:134
Phase 2:59
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (448 trials with phase data)• Click on a phase to view related trials

Not Applicable
192 (42.9%)
Phase 1
134 (29.9%)
Phase 2
59 (13.2%)
Phase 4
34 (7.6%)
Phase 3
24 (5.4%)
Early Phase 1
5 (1.1%)

The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)

Phase 2
Recruiting
Conditions
Prostate Cancer (Adenocarcinoma)
OligoProgressive Metastatic Disease
Castration Resistant Metastatic Prostate Cancer
Radiotherapy
First Posted Date
2025-06-26
Last Posted Date
2025-06-26
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
35
Registration Number
NCT07038304
Locations
🇳🇱

UMC Groningen, Groningen, Netherlands

🇳🇱

Radboud Umc, Nijmegen, Netherlands

The Added Value of Three-dimensional Electroanatomic Mapping For Accurate Delivery Of Pulsed Field Ablation In The Pulmonary Veins Compared To Pulsed Field Ablation With Fluoroscopy And/Or Intracardiac Echocardiography Alone In The Treatment Of Atrial Fibrillation: MAP-PFA Study

Not Applicable
Not yet recruiting
Conditions
Atrial Fibrillation (AF)
First Posted Date
2025-06-11
Last Posted Date
2025-06-11
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
32
Registration Number
NCT07014423
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

🇳🇱

Erasmus Medical Center, Rotterdam, Netherlands

Fluid Management and Individualized Resuscitation in Sepsis

Not Applicable
Not yet recruiting
Conditions
Sepsis
Critical Care, Fluid Resuscitation
Fluid Responsiveness
Shock
Personalized Medicine
Emergency Medicine
First Posted Date
2025-06-06
Last Posted Date
2025-06-06
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
174
Registration Number
NCT07009665
Locations
🇳🇱

University Medical Centre Groningen, Groningen, Netherlands

SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC

Phase 1
Not yet recruiting
Conditions
Nasopharyngeal Carcinoma (NPC)
First Posted Date
2025-05-21
Last Posted Date
2025-05-21
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
10
Registration Number
NCT06982300
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

Prediction of ICG for Skin Necrosis in Mastectomy With Immediate Reconstruction

Not yet recruiting
Conditions
Breast Cancers
Skin Necrosis
Mastectomy and Breast Reconstruction
First Posted Date
2025-05-04
Last Posted Date
2025-05-04
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
50
Registration Number
NCT06956443
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 117
  • Next

News

Team Sports Enhance Cognitive Development and Academic Success in Children, Studies Show

Children participating in team sports like soccer and volleyball demonstrate superior executive function skills compared to those in individual sports or no sports, according to a Dutch longitudinal study published in JAMA Network Open.

Tirzepatide Shows Promising Renal Benefits in Type 2 Diabetes Patients Through SURPASS Trials Analysis

Post hoc analysis of SURPASS trials reveals tirzepatide significantly reduced urine albumin-to-creatinine ratio by up to 26.3% compared to control groups in type 2 diabetes patients.

Brexu-Cel Demonstrates High Response Rates in BTK Inhibitor-Naive Relapsed/Refractory MCL

Brexucabtagene autoleucel (brexu-cel) shows a 91% overall response rate (ORR) in patients with relapsed/refractory mantle cell lymphoma (MCL) who are BTK inhibitor-naive.

Ozempic Shows Promise in Curbing Kidney Disease in Obese Individuals Without Diabetes

Semaglutide, the active agent in Ozempic and Wegovy, demonstrates a significant 52% reduction in kidney damage among obese individuals without diabetes.

ASN Kidney Week 2024: Novel Clinical Trials Highlight Advances in Kidney Disease Treatment

Finerenone shows similar long-term kidney function patterns to placebo in heart failure patients, while reducing protein leakage, suggesting potential benefits in specific outcomes.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.